Fosun Pharma subsidiary gains approval for XH-S003 clinical trial

Shanghai Fosun Pharmaceutical (HKEX: 2196) announced that its subsidiary, S-INFINITY Pharmaceuticals, has received approval from the National Medical Products Administration of China to begin clinical trials for XH-S003 capsules. XH-S003 is a novel small molecule inhibitor of the complement system, targeting diseases involving abnormal complement activation, including paroxysmal nocturnal hemoglobinuria (PNH). The company intends to initiate a Phase II clinical trial in China, excluding Hong Kong, Macau, and Taiwan, upon fulfilling specified conditions. As of February 2025, Fosun Pharma had invested approximately RMB 106 million in the research and development of XH-S003. The global market for major PNH drugs reached approximately US$1.247 billion in 2024, according to IQVIA MIDAS™™. The company cautioned that the development and launch of new drugs involve inherent risks and uncertainties.